32
Active Trials
15
Phase 1
20
Phase 2
10
Phase 3
3
Therapeutic Areas
Portfolio Concentration: 78% of active trials in Oncology
Oncology
25 active / 40 total
Solid Tumor (Advanced)
7 active
1 Ph3
12 total since 2015
NSCLC
4 active
1 Ph3
4 total since 2015
Lung Cancer (General)
3 active
1 Ph3
3 total since 2015
Colorectal Cancer
2 active
2 total since 2015
Breast Cancer
2 active
2 total since 2015
Pancreatic Cancer
1 active
3 total since 2015
Triple Negative Breast Cancer
1 active
2 total since 2015
Prostate Cancer
1 active
1 Ph3
2 total since 2015
Glioblastoma
1 active
1 total since 2015
ALL
1 active
1 total since 2015
Head and Neck Cancer
1 active
1 Ph3
1 total since 2015
Endometrial Cancer
1 active
1 Ph3
1 total since 2015
Melanoma
0 active
2 total since 2015
SCLC
0 active
1 total since 2015
Gastric Cancer
0 active
1 total since 2015
Esophageal Cancer
0 active
1 total since 2015
Cholangiocarcinoma
0 active
1 total since 2015
Infectious Disease
7 active / 36 total
Immunology
0 active / 5 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)